A Pivotal phase III trial of SPN-604 (Oxtellar XR) for Bipolar disorders
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Bipolar disorders
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 05 Nov 2019 According to Supernus Pharmaceuticals media release, this trial has been initiated in the fourth quarter of 2019.
- 05 Nov 2019 Status changed from planning to recruiting, according to Supernus Pharmaceuticals media release.
- 06 Aug 2019 According to Supernus Pharmaceuticals media release, trial is expected to start in the fourth quarter of 2019